Real-world 8-Year outcomes of patients with early-stage HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

Sirico, Marianna (2026) Real-world 8-Year outcomes of patients with early-stage HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab, [Dissertation thesis], Alma Mater Studiorum Università di Bologna. Dottorato di ricerca in Oncologia, ematologia e patologia, 38 Ciclo.
Documenti full-text disponibili:
[thumbnail of tesi dottorato 2026_.pdf] Documento PDF (English) - Richiede un lettore di PDF come Xpdf o Adobe Acrobat Reader
Disponibile con Licenza: Creative Commons: Attribuzione 4.0 (CC BY 4.0) .
Download (629kB)

Abstract

The Anti-Human Epithelial Growth factor 2 (HER2) monoclonal humanized antibodies represent a major advance in the treatment of patients with HER2-positive (HER2+) breast cancer (BC), having become the standard of care in the neoadjuvant, adjuvant, and metastatic settings, mostly in combination with chemotherapy. In the adjuvant setting, four phase 3 randomized trials involving more than 8000 patients showed that when trastuzumab was administered in combination with or after chemotherapy, the risk of recurrence was decreased by approximately 50%. However, these trials focused largely on patients with stage II or stage III HER2+ BC. Until 2015, no single standard treatment regimen was recommended for patients with stage I HER2-positive BC. To address this issue, Tolaney et al. have conducted a single arm adjuvant trial with paclitaxel (12 weeks) combined with 1 year of trastuzumab. Eligible patients had to have confirmed HER2+ early BC, <3cm and node-negative disease. The primary endpoint was disease-free survival (DFS). A 3-year DFS rate was 98.7% (95% confidence interval [CI], 97.6 to 99.8). After a median follow-up of 6.5 years, the updated results have shown a 7-year DFS of 93% (95% CI, 90.4 to 96.2) 7. Despite being a phase II single-arm trial, these results established adjuvant weekly paclitaxel plus trastuzumab in HER2+ stage I BC as an option in several guidelines. One of the APT trial limitations is the lack of data about used endocrine therapy (ET), which was left to the treating physician's discretion. In the APT trial, 132 patients were younger than 50 years old. However, the information about ET and ovarian function suppression is unknown. Interestingly, the chemo-induced amenorrhea concerned 28% of 64 evaluable patients from APT trial. Our study aims to report the real-world data of patients with stage I HER2+ eBC treated according to the APT regimen in our centre.

Abstract
Tipologia del documento
Tesi di dottorato
Autore
Sirico, Marianna
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
38
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
Breast Cancer, Real Word data, adjuvant,
Data di discussione
8 Settembre 2026
URI

Altri metadati

Statistica sui download

Gestione del documento: Visualizza la tesi

^